¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Other forms of systemic lupus erythematosus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus tumidus
    ºñ´ë·çǪ½º, ºÎÀº·çǪ½º
  • lupus vulgaris
    º¸Åë·çǪ½º
  • diffuse systemic sclerosis
    ±¤¹üÀ§Àü½Å°æÈ­Áõ
  • idiopathic systemic fibrosis
    Ư¹ßÀü½Å¼¶À¯Áõ
  • portal-systemic encephalopathy
    ¹®¸ÆÀü½Å¼øÈ¯(¼º)³úº´(Áõ)
  • progressive systemic sclerosis
    ÁøÇàÀü½Å°æÈ­Áõ
  • systemic
    1. Àü½Å¼º- 2. ü°èÀû
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic circulation
    ¿Â¸ö¼øÈ¯, ü¼øÈ¯
  • systemic death
    Àü½Å»ç¸Á
  • systemic disease
    Àü½Åº´
  • systemic embolism
    Àü½Å»öÀüÁõ
  • systemic hypotension
    Àü½ÅÀúÇ÷¾Ð
  • systemic infection
    Àü½Å°¨¿°
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus vulgaris
    º¸Åë·çǪ½º
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic arachnidism
    Àü½Å°Å¹Ìµ¶Áõ
  • systemic circulation
    ¿Â¸ö¼øÈ¯, ü¼øÈ¯
  • diffuse systemic sclerosis
    ±¤¹üÀ§Àü½Å°æÈ­Áõ
  • systemic death
    Àü½Å»ç
  • systemic disease
    Àü½Åº´
  • portal-systemic encephalopathy
    ¹®¸ÆÀü½Å¼øÈ¯³úº´Áõ
  • systemic embolism
    Àü½Å»öÀüÁõ
  • idiopathic systemic fibrosis
    Ư¹ßÀü½Å¼¶À¯Áõ
  • infantile systemic hyalinosis
    À¯¾ÆÀü½ÅÀ¯¸®ÁúÁõ
  • systemic hypotension
    Àü½ÅÀúÇ÷¾Ð
  • systemic infection
    Àü½Å°¨¿°
  • systemic lesion
    °èÅ뺴ÅÍ
  • systemic mastocytosis
    Àü½Åºñ¸¸¼¼Æ÷Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇà(¼º) Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõ îñãóàõ Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõîñãóàõÌãûùñø).
  • reactive systemic amyloidosis
    ¹ÝÀÀ¼º Àü½Å À¯ÀüºÐÁõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • discoid lupus erythematosus
    ¿øÆÇ»ó È«¹Ý(ê­÷ùßÒûõÚè)·çǪ½º
  • disseminated lupus erythematosus
    ÆÄÁ¾¼º È«¹Ý¼º·çǪ½º.
  • erythematodes<³ª> lupus erythematosus
    ¿¡¸®Å׸¶Åäµ¥½º, È«¹Ý¼º ·çǪ½º.
  • hypertrophic lupus erythematosus
    ºñÈļºÈ«¹Ý¼º³¶Ã¢
  • lupus erythematosus panniculitis
    È«¹Ý¼º ·çǪ½º Áö¹æÃþ¿°
  • lupus disseminatus erythematosus ³ª
    ÆÄÁ¾»ó È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus = LE ³ª
    È«¹Ý¼º ·çǪ½º
  • lupus erythematosus =LE ³ª
    È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus =le ³ª
    È«¹Ý¼º ·çǪ½º(ûõÚèàõ ¡­)
  • lupus erythematosus cell
    È«¹Ý¼º³¶Ã¢¼¼Æ÷
  • lupus erythematosus cell = LE cell
    È«¹Ý¼º ·çǪ½º¼¼Æ÷(¡­á¬øà)
  • lupus erythematosus disseminatus ³ª
    ÆÄÁ¾»ó(÷ëðúßÒ)È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • lupus erythematosus factor =LE f.
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­).
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾çÁõÈıº(ûõÚèàõ¡­åÆñøý¦ÏØ )
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SLEDAI systemic lupus erythematosus disease activity index
DLE Discoid Lupus Erythematosus
LE Lupus Erythematosus; È«¹Ý¼º ·çǪ½º(³¶Ã¢)
SCLE Subacute Cutaneous Lupus Erythematosus
CDLE chronic discoid lupus erythematosus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SCLE Subacute Cutaneous Lupus Erythematosus
SLAM Systemic Lupus Activity Measure
SLE Systemic Lupus Erytematosus
SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of Rheumatology
SLE systemic Lupus Erythematodes
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chilblain lupus
    µ¿Ã¢ ·çǪ½º
  • discoid lupus chronicus
    ¸¸¼º ¿øÆÇ»ó ³¶Ã¢
  • drug-induced lupus
    ¾à¹° À¯¹ß ·çǪ½º
  • lupus
    ·çǪ½º, ³¶Ã¢
    óÀ½¿¡´Â ÆÄ±«¼º ÇǺΠº´º¯¿¡ ºÙÀÎ ¸íĪÀ¸·Î °©»ó¼±Á¾¿¡ À¯·¡Çϰí, ¸¸¼ºÀÌ¸ç ºñ´ë, Èí¼ö, ±Ë¾ç µîÀ» µ¿¹ÝÇÏ´Â ±¹¼Ò º´º¯.
  • lupus hypertrophicus
    ºñÈļº ·çǪ½º
  • lupus nephritis
    ³¶Ã¢¼º ½ÅÀå¿°
  • lupus vulagris
    ½É»ó¼º ³¶Ã¢, ½É»ó¼º ·çǪ½º, º¸Åë ·çǪ½º
    ÇǺÎÀÇ ¿ø¹ß¼º °áÇÙÀ¸·Î ±«¾ç¼ºÀÇ ±¸Áø¼º ¼Ò°áÀýÀ» º¸ÀÌ¸ç Æ¯È÷ ¾ó±¼¿¡ Àß ¹ß»ýÇÑ´Ù.
  • lupus-like syndrome
    ³¶Ã¢ ¾ç»óÀÇ ÁõÈıº
  • portal-systemic venous collateral circulation
    °£ ¹®¸Æ-Àü½Å Á¤¸ÆÀÇ ÃøÁö ¼øÈ¯
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å °æÈ­Áõ, ÁøÇ༺ Àü½Å¼º °æÈ­Áõ, ÁøÇ༺ Àü½Å¼º °øÇÇÁõ
  • surgically contructed systemic-pulmonary shunts
    ¿Ü°úÀûÀ¸·Î Çü¼ºÇØÁØ Àü½Å-Æó¼º ´Ü¶ô
  • systemic adverse effect
    Àü½Å¼º ºÎÀÛ¿ë
  • systemic blood pressure
    üÇ÷¾Ð
  • systemic circulation
    ´ë¼øÈ¯, ü¼øÈ¯
    ½ÉÀåÀÇ Á½ɽǿ¡¼­ ´ëµ¿¸ÆÀ¸·Î ³ª°£ Ç÷¾×ÀÌ Àü½ÅÀ» ÇÑ ¹ÙÄû µ· ´ÙÀ½, ´ëÁ¤¸ÆÀ» ÅëÇØ ¿ì½É¹æÀ¸·Î µ¹¾Æ¿À´Â ¼øÈ¯. ü¼øÈ¯À̶ó°íµµ ÇÑ´Ù. À̰ÍÀº Æó ¼øÈ¯À» ¼Ò¼øÈ¯À̶ó°í ÇÏ´Â °Í°ú ºñ±³ÇÏ¿© ºÙÀÎ ¸íĪÀÌ´Ù. Á½ɽǿ¡¼­ ´ëµ¿¸ÆÀ¸·Î ³ª¿Í ¼Òµ¿¸Æ, ¸ð¼¼Ç÷°üÀ» Áö³ª ¼ÒÁ¤¸Æ, ´ëÁ¤¸ÆÀ» °æÀ¯ÇÏ¿© ¿ì½É¹æÀ¸·Î µ¹¾Æ¿À´Â °æ·ÎÀÌ´Ù. ¼ÒÈ­±â °èÅë¿¡¼­ ³ª¿Â Á¤¸ÆÇ÷Àº ¹®¸Æ¿¡ ¸ð¿© °£À¸·Î µé¾î°¬´Ù°¡ ´Ù½Ã ¸ð¼¼Ç÷°üÀ¸·Î °¥¶óÁø ´ÙÀ½ °£Á¤¸ÆÀ¸·Î µé¾î°£´Ù.
  • systemic degenerative joint disease
    Àü½Å¼º ÅðÇ༺ °üÀý Áúȯ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
other-directed Pertaining to a person readily influenced by the attitudes of others.
(05 Mar 2000)
transferases (other substituted phosphate groups) <enzyme> A class of enzymes that transfers substituted phosphate groups.
Registry number: EC 2.7.8
(12 Dec 1998)
accole forms A term applied to the manner in which the ring stage of Plasmodium falciparum parasitises the marginal portion of erythrocytes.
Synonym: accole forms.
(05 Mar 2000)
applique forms A term applied to the manner in which the ring stage of Plasmodium falciparum parasitises the marginal portion of erythrocytes.
Synonym: accole forms.
(05 Mar 2000)
atypical bacterial forms Microorganisms that have undergone greater changes than normal in morphology, physiology, or cultural characteristics.
(12 Dec 1998)
dosage forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. They include capsules, liniments, ointments, pharmaceutical solutions, powders, tablets, etc.
(12 Dec 1998)
forms and records control A management function in which standards and guidelines are developed for the developing, maintaining, and handling of forms and records.
(12 Dec 1998)
forms of DNA i, II and III Refers to circular DNA removed from viruses and as plasmids. Form I is the DNA in its normal, supercoiled form. Form II is the DNA after one of the two strands has been nicked (cut apart), and is circular. Form III is the DNA after both strands have been broken, and is linear.
(09 Oct 1997)
l forms Bacterial variants, unable to form a complete cell wall, which are formed in cultures by various bacteria; granules (l bodies) appear, unite, and grow into amorphous bodies which multiply and give rise to bacterial cells morphologically indistinguishable from the parent strain.
(12 Dec 1998)
pemphigus erythematosus An eruption involving sun-exposed skin, especially the face; the lesions are scaling erythematous macules and blebs, combining the clinical features of both lupus erythematosus and pemphigus vulgaris; bullae are subcorneal; probably a variant of pemphigus foliaceus.
Synonym: Senear-Usher disease, Senear-Usher syndrome.
(05 Mar 2000)
rheumatoid arthritis, systemic-onset juvenile Also known as systemic-onset juvenile chronic arthritis. Still's disease presents with systemic (bodywide) illness including high intermittent fever, a salmon-coloured skin rash, swollen lymph glands, enlargement of the liver and spleen, and inflammation of the lungs (pleuritis) and around the heart (pericarditis). The arthritis may not be immediately apparent but it does appear and may persist after the systemic symptoms are gone.
(12 Dec 1998)
portal-systemic anastomoses Naturally-occurring venous communications between tributaries of the portal venous system and tributaries of the systemic venous system. The major portal-systemic anastomoses include: 1) oesophageal branches of left gastric vein with oesophageal veins, 2) superior rectal vein with middle and inferior rectal veins, 3) paraumbilical veins with subcutaneous veins of anterior abdominal wall, 4) retroperitoneal veins with venous branches of veins of the colon and bare area of the liver, and 5) a patent ductus venosus connecting left branch of portal vein to inferior vena cava (rare). These anastomoses are important clinically, providing collateral circulation during portal obstruction or hypertension, at which time they may become varicose.
See: caput medusae, oesophageal varices, haemorrhoids.
Surgically-created communications between the portal vein and the inferior vena cava or their tributaries, to relieve portal hypertension.
Synonym: portacaval anastomoses.
(05 Mar 2000)
portal-systemic encephalopathy An encephalopathy associated with cirrhosis of the liver, attributed to the passage of toxic nitrogenous substances from the portal to the systemic circulation; cerebral manifestations may include coma.
Synonym: hepatic encephalopathy.
(05 Mar 2000)
scleroderma, systemic A chronic, progressive dermatosis characterised by boardlike hardening and immobility of the affected skin, with visceral involvement, especially of lungs, oesophagus, kidneys and heart. It may be accompanied by calcinosis, raynaud's phenomenon, and telangiectasis (crest syndrome). It includes acrosclerosis and sclerodactyly.
(12 Dec 1998)
systemic <anatomy> Pertaining to or affecting the body as a whole.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á